CAMBRIDGE, England & BOSTON & VILLIGEN, Switzerland--(BUSINESS WIRE)--Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based ...

In drug discovery, virtual screening is a fast and cost-effective way of narrowing down vast chemical libraries to identify the most promising hits, reducing synthesis and testing requirements while ...

Scientists led by a team at the Medical Research Council (MRC) Mitochondrial Biology Unit, University of Cambridge, have worked out how a molecular machine found in mitochondria—the “powerhouses” of ...

KAIST (President Kwang Hyung Lee) announced on the 10th that a research team led by Professor Woo Youn Kim in the Department of Chemistry has developed an AI model named BInD (Bond and ...

University of Virginia School of Medicine scientists have developed a bold new approach to drug development and discovery that could dramatically accelerate the creation of new medicines. UVA's ...

Key segments positively impacting the market include chemistry services, with the largest share dominant due to technologies such as combinatorial chemistry and structure-based drug design. In the ...

In the wee hours of an October morning, David Baker, a protein biologist at the University of Washington (UW), received the most-awaited phone call in a scientist’s career. Halfway around the world, ...

Structure Therapeutics Inc. has announced the selection of its lead oral small molecule amylin receptor agonist, ACCG-2671, which shows promising preclinical results including potent target engagement ...